Show simple item record

dc.contributor.authorMuthuri, Stella G
dc.contributor.authorVenkatesan, Sudhir
dc.contributor.authorMyles, Puja R
dc.contributor.authorLeonardi-Bee, Jo
dc.contributor.authorLim, Wei Shen
dc.contributor.authorAl Mamun, Abdullah
dc.contributor.authorAnovadiya, Ashish P
dc.contributor.authorAraujo, Wildo N
dc.contributor.authorAzziz-Baumgartner, Eduardo
dc.contributor.authorBaez, Clarisa
dc.contributor.authorBantar, Carlos
dc.contributor.authorBarhoush, Mazen M
dc.contributor.authorBassetti, Matteo
dc.contributor.authorKeijzers, Gerben
dc.contributor.authoret al.
dc.description.abstractBackground: The impact of neuraminidase inhibitors (NAIs) on influenza-related pneumonia (IRP) is not established. Our objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1)pdm09 virus infection. Methods: A worldwide meta-analysis of individual participant data from 20 634 hospitalised patients with laboratory-confirmed A(H1N1)pdm09 (n = 20 021) or clinically diagnosed (n = 613) 'pandemic influenza'. The primary outcome was radiologically confirmed IRP. Odds ratios (OR) were estimated using generalised linear mixed modelling, adjusting for NAI treatment propensity, antibiotics and corticosteroids. Results: Of 20 634 included participants, 5978 (29·0%) had IRP; conversely, 3349 (16·2%) had confirmed the absence of radiographic pneumonia (the comparator). Early NAI treatment (within 2 days of symptom onset) versus no NAI was not significantly associated with IRP [adj. OR 0·83 (95% CI 0·64-1·06; P = 0·136)]. Among the 5978 patients with IRP, early NAI treatment versus none did not impact on mortality [adj. OR = 0·72 (0·44-1·17; P = 0·180)] or likelihood of requiring ventilatory support [adj. OR = 1·17 (0·71-1·92; P = 0·537)], but early treatment versus later significantly reduced mortality [adj. OR = 0·70 (0·55-0·88; P = 0·003)] and likelihood of requiring ventilatory support [adj. OR = 0·68 (0·54-0·85; P = 0·001)]. Conclusions: Early NAI treatment of patients hospitalised with A(H1N1)pdm09 virus infection versus no treatment did not reduce the likelihood of IRP. However, in patients who developed IRP, early NAI treatment versus later reduced the likelihood of mortality and needing ventilatory support.
dc.publisherJohn Wiley and Sons
dc.relation.ispartofjournalInfluenza and Other Respiratory Viruses
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchHealth services and systems
dc.subject.fieldofresearchPublic health
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsInfectious Diseases
dc.titleImpact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: An individual participant data meta-analysis
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationMuthuri, SG; Venkatesan, S; Myles, PR; Leonardi-Bee, J; Lim, WS; Al Mamun, A; Anovadiya, AP; Araujo, WN; Azziz-Baumgartner, E; Baez, C; Bantar, C; Barhoush, MM; Bassetti, M; Keijzers, G; et al., Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: An individual participant data meta-analysis, Influenza and Other Respiratory Viruses, 2016, 10 (3), pp. 192-204
gro.hasfulltextNo Full Text
gro.griffith.authorKeijzers, Gerben

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record